<<They couldn't even find a subgroup where it worked well. This is one negative result that deserves a thorough article analyzing it.>>
Maybe they did?
Sunday
1:00 PM -
5:00 PM 2523 - Subset analyses of INTACT results for gefitinib (ZD1839) when combined with platinum-based chemotherapy (CT) for advanced non-small-cell lung cancer (NSCLC).
Authors: R. S. Herbst, G. Giaccone, J. Schiller, V. Miller, R. Natale, P. Rennie, J. Ochs, A. Fandi, J. Grous, D. Johnson; University of Texas MD Anderson Cancer Center, Houston, TX; Free University Hospital, Amsterdam, Netherlands; University of Wisconsin Hospital and Clinics, Madison, WI; Memorial Sloan-Kettering Cancer Center, New York, NY; Cedars-Sinai Comprehensive Cancer Center, Beverly Hills, CA; AstraZeneca, Macclesfield, UK; AstraZeneca, Wilmington, DE; Vanderbilt-Ingram Cancer Center, Nashville, TN
Presenter: Roy S. Herbst
Chair(s): Alex A. Adjei; Mark A. Socinski
Keyword(s): Gefitinib, Epidermal growth factor receptor tyrosine inhibitors, ZD1839
Category: Non-Small-Cell Lung Cancer
Lung Cancer
Poster Discussion
S106
<<I guess attention will now shift to Tarceva.>>
More broad. What is makeup of the various TK growth factor that determine response to certain drugs, as well that control aggressiveness of the cancer?
Miljenko |
